Finance analyst: Eli Lilly deals hard blow to Novo Nordisk with new data
While many Danish analysts were not overly concerned by Eli Lilly's novel data for tirzepatide as a rival to Novo Nordisk's semaglutide, financial analyst Jefferies sees the new data as a considerable threat against Novo Nordisk's market shares.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.